ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Joshua Richter discusses the MOA of CELMoDs and efficacy of MeziKd (Video 1/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Joshua Richter discusses the MOA of CELMoDs and efficacy of MeziKd (Video 1/3)

    Published Aug 5, 2026

    J

    Joshua Richter, MD

    Medical Professional

    Mezigdomide MOA & MeziKd Efficacy

    More in this series: SUCCESSOR-2_2026
    Dr. Joshua Richter reviews the safety profile and AE management of MeziKd (Video 2/3)

    Dr. Joshua Richter reviews the safety profile and AE management of MeziKd (Video 2/3)

    MeziKd Safety Profile

    Joshua Richter, MD
    Hematologic Malignancies
    Dr. Joshua Richter highlights the patient types that may benefit most from mezigdomide (Video 3/3)

    Dr. Joshua Richter highlights the patient types that may benefit most from mezigdomide (Video 3/3)

    Patient Selection for Mezigdomide

    Joshua Richter, MD
    Hematologic Malignancies
    Related Videos
    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Eytan Stein, MD
    Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)

    Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)

    Wade Iams, MD
    What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)

    What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)

    Rahul Banerjee, MD
    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Eytan Stein, MD